Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Current Breast Cancer Reports
Erschienen in: Current Breast Cancer Reports 2/2017

19.05.2017 | Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

New Approaches for Tailoring the Use of Radiotherapy in Early-Stage Breast Cancer

verfasst von: Julia White

Erschienen in: Current Breast Cancer Reports | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The majority of women diagnosed with early-stage breast cancer will undergo radiotherapy. Clinical decisions regarding the delivery of radiotherapy are typically based on clinical and pathologic factors. In contrast, systemic therapy clinical decisions incorporate specific breast cancer biology. This review will focus on how breast cancer biology may help tailor radiotherapy for early-stage patients.

Recent Findings

Radiotherapy for early-stage breast cancer is typically delivered for breast conservation. Regional nodal radiotherapy use in early-stage disease is expected to expand in the wake of recent clinical trial publications demonstrating improved disease-free survival in those with one to three axillary nodal metastases. There is a growing body of data demonstrating that intrinsic breast cancer subtypes and luminal multigene assays developed for systemic therapy are also associated with local regional recurrence.

Summary

Including tumor biology in addition to standard clinical and pathological factors may lead to a more tailored use of radiotherapy in early-stage breast cancer.
Literatur
1.
2.
Sareigo J. Regional variation in breast cancer treatment throughout the United States. Am J Surg. 2008;196:572–4.CrossRef
3.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual, 7th ed. France: Springer; 2010.
4.
Agarwal S, Pappas L, Neumayer L, et al. Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer. JAMA Surg. 2014;149(3):267–74.CrossRefPubMed
5.
EBCTCG (Early Breast Cancer Trialists’ Collaborative Group). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomized trials. Lancet. 2014;383:2127–35.CrossRef
6.
Poortmans PM, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;374(4):317–27.CrossRef
7.
8.
Sorlie T, Perou C, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS. 2001;98(19):10869–74.CrossRefPubMedPubMedCentral
9.
Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Investig. 2008;26:1–10.CrossRef
10.
Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24:S26–35.CrossRefPubMed
11.
Sineshaw HM, Gaudet M, Ward EM, et al. Association of race/ethnicity, socioeconomic status, and breast cancer subtypes in the National Cancer Data Base (2010–2011). Breast Cancer Res Treat. 2014;145:753–63.CrossRefPubMed
12.
Harris L, Ismaila N, McShane L, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:1134–50.CrossRefPubMedPubMedCentral
13.
Tuttle T, Jarosek S, Habermann E, et al. Omission of radiation therapy after breast-conserving surgery in the United States. Cancer. 2012;118:2004–13.CrossRefPubMed
14.
Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;366(9503):2087–106.CrossRefPubMed
15.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomized trials. Lancet. 2011;378:1707–16.CrossRef
16.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials. Lancet. 2011;378:771–84.CrossRef
17.
Pegram MD, Pauletti G, Slamon DJ, et al. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat. 1998;52(1–3):65–77.CrossRefPubMed
18.
Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31:2382–7.CrossRefPubMedPubMedCentral
19.
Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002;20:4141–9.CrossRefPubMed
20.
Fyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004;351:963–70.CrossRefPubMed
21.
Arvold N, Taghian A, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 2010;29:3885–91.CrossRef
22.
Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28:1684–91.CrossRefPubMed
23.
• Liu F, Shi W, Done S, et al. Identification of a low-risk luminal a breast cancer cohort that may not benefit from breast radiotherapy. J Clin Oncol. 2015;33:2035–40. This manuscript demonstrated the importance of intrinsic subtype reconstructed by IHC and its relation to LRR in clinical trial samples from a population of all hormone-sensitive, node-negative breast cancer that was randomized to receive radiotherapy or observation after lumpectomy. By combining luminal A intrinsic subtype and clinical pathologic factors, they identified a cohort that had very low LRR after lumpectomy without radiotherapy. CrossRefPubMed
24.
Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717–29.CrossRefPubMed
25.
Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of loco regional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010;28:1677–83.CrossRefPubMedPubMedCentral
26.
Solin LJ, Gray R, Goldstein LJ, et al. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat. 2012;134:683–92.CrossRefPubMedPubMedCentral
27.
Fitzal F, Filipits M, Fesl C, et al. Predicting local recurrence using PAM50 in postmenopausal endocrine responsive breast cancer patients. J Clin Oncol. 2014;32:5s. (suppl; abstr 1008)
28.
Fitzal F, Filipits M, Ruduas M, et al. The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomized within the prospective ABCSG 8 trial. Brit J Ca. 2015;112:1405–10.CrossRef
29.
Drukker C, Elias S, Nijenhuis M, et al. Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis. Breast Cancer Res Treat. 2014;148:599–613.CrossRefPubMed
30.
Kyndi M, Sørensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:1419–26.CrossRefPubMed
31.
Kim M, Dawood S, Allen P, et al. Hormone receptor status influences the locoregional benefit of trastuzumab in patients with non-metastatic breast cancer. Cancer. 2012;118(20):4936–43.CrossRefPubMedPubMedCentral
32.
Wang SL, Li YX, SONG YW, et al. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy. Int J Radiation Oncology Biol Phys. 2011;80(4):1095–101.CrossRef
33.
Wu SG, He ZY, Li Q, et al. Predictive value of breast cancer molecular subtypes in Chinese patients with four or more positive nodes after postmastectomy radiotherapy. Breast. 2012;21:657–61.CrossRefPubMed
34.
• Tramm T, Mohammed H, Myhre S, et al. Development and validation of a gene profile predicting benefit of postmastectomy radiotherapy in patients with high-risk breast cancer: a study of gene expression in the DBCG 82bc cohort. Clin Cancer Res. 2014;20(20):5272–80. This manuscript reports on a seven-gene expression profile that was developed and validated from tissue samples collected on the DBCG82bc post-mastectomy clinical trials that are prognostic for LRR and predict radiotherapy benefit. Additional validation in other datasets is warranted for this assay that could potentially become an important clinical tool. CrossRefPubMed
35.
Tramm T, Kyndi M, Myhre S, et al. Relationship between the prognostic and predictive value of the intrinsic subtypes and a validated gene profile predictive of loco-regional control and benefit from post-mastectomy radiotherapy in patients with high-risk breast cancer. Acta Oncol. 2014;53:1337–46.CrossRefPubMed
36.
• Mamounas EP, Liu Q, Paik S, et al. 21-gene recurrence score and locoregional recurrence in node-positive/ER-positive breast cancer treated with chemo-endocrine therapy. JNCI J Natl Cancer Inst. 2017;109(4):djw259. This analysis demonstrated in tissue samples collected on the NSABP B-28 clinical trial that a biological factor like the Oncotype RS assay is prognostic for LRR in node-positive breast cancer treated with chemo-endocrine therapy and without regional nodal radiotherapy. Low LRR was reported in the low-risk or ≤18 RS groups, including those with four or more positive lymph nodes. CrossRefPubMed
37.
Woodward WA, Barlow WE, Jagsi R, et al. The 21-gene recurrence score and locoregional recurrence rates in patients with node-positive breast cancer treated on SWOG S8814. Int J Radiat Oncol Biol Phys. 96(2). S1-S268, e1-e717. 2016.
38.
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72.CrossRefPubMed
39.
Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of loco-regional recurrence following neoadjuvant chemotherapy: results from combined analysis of NSABP B-18 and B-27. J Clin Oncol. 2012;30(32):3960–6.CrossRefPubMedPubMedCentral
Metadaten
Titel
New Approaches for Tailoring the Use of Radiotherapy in Early-Stage Breast Cancer
verfasst von
Julia White
Publikationsdatum
19.05.2017
Verlag
Springer US
Erschienen in
Current Breast Cancer Reports / Ausgabe 2/2017
Print ISSN: 1943-4588
Elektronische ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-017-0240-0

Weitere Artikel der Ausgabe 2/2017

Current Breast Cancer Reports 2/2017 Zur Ausgabe

Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

Management of Rare Breast Tumors and Male Breast Cancer

Psycho-Oncology and Supportive Care (E Shinn and C Fagundes, Section Editor)

Racial/Ethnic Disparities in Breast Cancer Incidence, Risk Factors, Health Care Utilization, and Outcomes in the USA

Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

Diagnostic Methods, Risk Factors, Prevention, and Management of Breast Cancer-Related Lymphedema: Past, Present, and Future Directions

Psycho-Oncology and Supportive Care (E Shinn and C Fagundes, Section Editors)

Mechanisms of Neurotoxic Symptoms as a Result of Breast Cancer and Its Treatment: Considerations on the Contribution of Stress, Inflammation, and Cellular Bioenergetics

Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

Current Trends in Localization Techniques for Non-palpable Breast Lesions: Making the Invisible Visible

Psycho-Oncology and Supportive Care (E Shinn and C Fagundes, Section Editors)

Caregiving Stress and Its Toll on Health From a Psychoneuroimmunological Perspective

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Prostatakarzinom: EU initiiert neues Screeningkonzept

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Blasenkarzinom – Biomarker statt Zytologie?

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

17.04.2024 | Mammakarzinom | Nachrichten

Adjuvante Brustkrebstherapie: Doppelt hält besser
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen